Literature DB >> 26913293

Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies.

Andrew C Birkeland1, J Chad Brenner2.   

Abstract

Personalized medicine, in which individual tumor genetics drive the selection of targeted therapies and treatment plans for each patient, has recently emerged as the next generation of cancer therapy. Unfortunately, personalized medicine trials have had limited success in tumors that have complex combinations of disruptive genomic events, which drive differential responses to targeted therapies. Here, we will use head and neck squamous cell carcinoma as a model for genetically complex disease and discuss novel approaches to enhance personalized medicine trials for these complicated cases.

Entities:  

Keywords:  HNSCC; Personalized Medicine; Sequencing

Year:  2015        PMID： 26913293      PMCID： PMC4762450          DOI： 10.18103/mra.v0i3.77

Source DB:  PubMed          Journal:  Med Res Arch        ISSN： 2375-1916


  64 in total

1.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

2.  Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer.

Authors:  Daniel J Givens; Lucy Hynds Karnell; Anjali K Gupta; Gerald H Clamon; Nitin A Pagedar; Kristi E Chang; Douglas J Van Daele; Gerry F Funk
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-12

3.  Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.

Authors:  Atsushi Imai; Benjamin D Zeitlin; Fernanda Visioli; Zhihong Dong; Zhaocheng Zhang; Sudha Krishnamurthy; Emily Light; Frank Worden; Shaomeng Wang; Jacques E Nör
Journal:  Cancer Res       Date:  2011-12-08       Impact factor: 12.701

Review 4.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Authors:  D Chen; M Frezza; S Schmitt; J Kanwar; Q P Dou
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

5.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

Review 6.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.

Authors:  Pasi A Jänne; Nathanael Gray; Jeff Settleman
Journal:  Nat Rev Drug Discov       Date:  2009-07-24       Impact factor: 84.694

7.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

8.  Randomized, controlled phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene therapy in treatment of oral cancer.

Authors:  S Liu; P Chen; M Hu; Y Tao; L Chen; H Liu; J Wang; J Luo; G Gao
Journal:  Cancer Gene Ther       Date:  2013-05-31       Impact factor: 5.987

9.  HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

Authors:  Ken Takezawa; Valentina Pirazzoli; Maria E Arcila; Caroline A Nebhan; Xiaoling Song; Elisa de Stanchina; Kadoaki Ohashi; Yelena Y Janjigian; Paula J Spitzler; Mary Ann Melnick; Greg J Riely; Mark G Kris; Vincent A Miller; Marc Ladanyi; Katerina Politi; William Pao
Journal:  Cancer Discov       Date:  2012-09-05       Impact factor: 39.397

10.  The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.

Authors:  V D'Amato; R Rosa; C D'Amato; L Formisano; R Marciano; L Nappi; L Raimondo; C Di Mauro; A Servetto; C Fusciello; B M Veneziani; S De Placido; R Bianco
Journal:  Br J Cancer       Date:  2014-05-13       Impact factor: 7.640
View more
  12 in total

1.  Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.

Authors:  Nicole L Michmerhuizen; Elizabeth Leonard; Aditi Kulkarni; J Chad Brenner
Journal:  Otorhinolaryngol Head Neck Surg       Date:  2016-06-07

Review 2.  The potential for tumor suppressor gene therapy in head and neck cancer.

Authors:  Andrew C Birkeland; Megan L Ludwig; Matthew E Spector; J Chad Brenner
Journal:  Discov Med       Date:  2016-01       Impact factor: 2.970

3.  The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines.

Authors:  Megan L Ludwig; Aditi Kulkarni; Andrew C Birkeland; Nicole L Michmerhuizen; Susan K Foltin; Jacqueline E Mann; Rebecca C Hoesli; Samantha N Devenport; Brittany M Jewell; Andrew G Shuman; Matthew E Spector; Thomas E Carey; Hui Jiang; J Chad Brenner
Journal:  Oral Oncol       Date:  2018-11-08       Impact factor: 5.337

Review 4.  Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer.

Authors:  Roberto N Solis; Dustin A Silverman; Andrew C Birkeland
Journal:  Curr Treat Options Oncol       Date:  2022-02-23

5.  Pathogenetic Analysis of Sinonasal Teratocarcinosarcomas Reveal Actionable β-catenin Overexpression and a β-catenin Mutation.

Authors:  Andrew C Birkeland; Sarah J Burgin; Megan Yanik; Megan V Scott; Carol R Bradford; Jonathan B McHugh; Scott A McLean; Stephen E Sullivan; Jacques E Nor; Erin L McKean; J Chad Brenner
Journal:  J Neurol Surg B Skull Base       Date:  2017-03-27

6.  Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma.

Authors:  Andrew C Birkeland; Susan K Foltin; Nicole L Michmerhuizen; Rebecca C Hoesli; Andrew J Rosko; Serena Byrd; Megan Yanik; Jacques E Nor; Carol R Bradford; Mark E Prince; Thomas E Carey; Jonathan B McHugh; Matthew E Spector; J Chad Brenner
Journal:  Oral Oncol       Date:  2017-03-10       Impact factor: 5.337

7.  Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.

Authors:  Brittny N Tillman; Megan Yanik; Andrew C Birkeland; Chia-Jen Liu; Daniel H Hovelson; Andi K Cani; Nallasivam Palanisamy; Shannon Carskadon; Thomas E Carey; Carol R Bradford; Scott A Tomlins; Jonathan B McHugh; Matthew E Spector; J Chad Brenner
Journal:  Head Neck       Date:  2016-02-05       Impact factor: 3.147

8.  A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.

Authors:  Andrew C Birkeland; Paul L Swiecicki; J Chad Brenner; Andrew G Shuman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-07-15

9.  Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.

Authors:  N L Michmerhuizen; J H Owen; M E Heft Neal; J E Mann; E Leonard; J Wang; J Zhai; H Jiang; J B McHugh; J C Brenner; M E P Prince
Journal:  J Neurooncol       Date:  2020-02-17       Impact factor: 4.506

Review 10.  The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck Cancer.

Authors:  Andrew C Birkeland; Megan L Ludwig; Taha S Meraj; J Chad Brenner; Mark E Prince
Journal:  Cancers (Basel)       Date:  2015-10-21       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.